Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,

Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,

#2246 Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): Characterisation of Prevalence and Prognosis in the Pulmonary Carcinoid Population

Introduction: DIPNECH is considered a rare condition and the natural history is poorly described. It is thought to give rise to pulmonary carcinoids (PCs) (>5mm) or tumourlets (≤5mm).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Hayes A

Authors: Hayes A, Banks J, Shah H, Luong T, Navalkissoor S,

Keywords: dipnech, diffuse idiopathic neuroendocrine cell hyperplasia, tumourlet, carcinoid, neuroendocrine tumor, multiple pulmonary nodules,

#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)

Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Manoharan P

Authors: Manoharan P, Navalkissoor S, Lamarca A, Calero J, Chan P,

Keywords: SomaKit, DOTATOC, GEP-NET,

#1416 Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Advanced Bronchial Neuroendocrine Tumours

Introduction: There is not established treatment pathway in advanced bronchial neuroendocrine tumours(bNETs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Koffas A

Authors: Koffas A, Popat R, Mohmaduvesh M, Quigley A, Navalkissoor S,

Keywords: PRRT,bronchial NETs,

#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues

Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Koffas A

Authors: Koffas A, Popat R, Dimitriou G, Quigley A, Navalkissoor S,

Keywords: PRRT, carcinoid syndrome,